These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Immunotherapy for the prevention and treatment of type 1 diabetes. Goudy KS; Tisch R Int Rev Immunol; 2005; 24(5-6):307-26. PubMed ID: 16318984 [TBL] [Abstract][Full Text] [Related]
23. Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes. Long SA; Thorpe J; Herold KC; Ehlers M; Sanda S; Lim N; Linsley PS; Nepom GT; Harris KM Cell Immunol; 2017 Sep; 319():3-9. PubMed ID: 28844471 [TBL] [Abstract][Full Text] [Related]
24. Progress towards the clinical use of CD3 monoclonal antibodies in the treatment of autoimmunity. Chatenoud L Curr Opin Organ Transplant; 2009 Aug; 14(4):351-6. PubMed ID: 19610168 [TBL] [Abstract][Full Text] [Related]
32. Regulatory mechanisms of immune tolerance in type 1 diabetes and their failures. Kuhn C; Besançon A; Lemoine S; You S; Marquet C; Candon S; Chatenoud L J Autoimmun; 2016 Jul; 71():69-77. PubMed ID: 27216249 [TBL] [Abstract][Full Text] [Related]
33. Evolving Antibody Therapies for the Treatment of Type 1 Diabetes. Ke Q; Kroger CJ; Clark M; Tisch RM Front Immunol; 2020; 11():624568. PubMed ID: 33679717 [TBL] [Abstract][Full Text] [Related]
34. Anti-CD3 mAbs for treatment of type 1 diabetes. Kaufman A; Herold KC Diabetes Metab Res Rev; 2009 May; 25(4):302-6. PubMed ID: 19319985 [TBL] [Abstract][Full Text] [Related]
35. Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes. Zhang L; Sosinowski T; Cox AR; Cepeda JR; Sekhar NS; Hartig SM; Miao D; Yu L; Pietropaolo M; Davidson HW J Autoimmun; 2019 Jan; 96():50-58. PubMed ID: 30122420 [TBL] [Abstract][Full Text] [Related]
36. [One step towards restoration of self-tolerance in human autoimmune diseases]. Chatenoud L Med Sci (Paris); 2007 Feb; 23(2):167-71. PubMed ID: 17291426 [TBL] [Abstract][Full Text] [Related]
37. The use of monoclonal antibodies to restore self-tolerance in established autoimmunity. Chatenoud L Endocrinol Metab Clin North Am; 2002 Jun; 31(2):457-75, ix. PubMed ID: 12092461 [TBL] [Abstract][Full Text] [Related]
38. Non-antigenic and antigenic interventions in type 1 diabetes. Rydén AK; Wesley JD; Coppieters KT; Von Herrath MG Hum Vaccin Immunother; 2014; 10(4):838-46. PubMed ID: 24165565 [TBL] [Abstract][Full Text] [Related]
39. Review on Monoclonal Antibodies (mAbs) as a Therapeutic Approach for Type 1 Diabetes. Agarwal G; Patel M Curr Diabetes Rev; 2024; 20(7):e310823220578. PubMed ID: 37653635 [TBL] [Abstract][Full Text] [Related]